AP surges on strong orders, AZN plunges after trial miss, LEVI slips on tariff outlook, MDA drops on dilution—read more.
Zacks.com on MSN
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
In the latest close session, Astrazeneca (AZN) was down 3.85% at $171.61. This move lagged the S&P 500's daily gain of 0.42%.
Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...
In the most recent trading session, Astrazeneca (AZN) closed at $185.68, indicating a +1.45% shift from the previous trading ...
Zacks Investment Research on MSN
Why AstraZeneca (AZN) dipped more than broader market today
Astrazeneca (AZN) ended the recent trading session at $183.86, demonstrating a -3.04% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
AstraZeneca (LSE:AZN) shares have been in focus after fresh collaboration news, with investors weighing how new research ...
AstraZeneca shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its ...
In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of £189.00. Unlock powerful investing tools and data-driven insights with TipRanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results